Atlas Trials

Olaparib in Patients With Recurrent Ovarian Cancer Wild Type for Germline and Somatic BRCA 1 and 2 Genes: The MITO 31 Translational Study

Clinical trial NCT04091204 · UNKNOWN

Trial details

NCT number
NCT04091204
Sponsor
National Cancer Institute, Naples
Status
UNKNOWN
Phase
Phase 2
Study type
INTERVENTIONAL
BRCA Wild Type Platinum Sensitive Recurrent Ovarian Cancer
Start date
2019-07-04
Primary completion
2023-09-01
Enrollment
200

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.